Objective assessment of the damaging effect of glucocorticoids (toxicity index) in patients with systemic lupus erythematosus
Open Access
- 16 December 2021
- journal article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (6), 111-116
- https://doi.org/10.14412/1996-7012-2021-6-111-116
Abstract
Systemic lupus erythematosus (SLE) is a multisystem disease characterized by chronic inflammation and damage to vital organs and systems. Despite the great success achieved in the treatment of SLE, glucocorticoids (GC) remain one of the main methods of therapy. The GC toxicity index is an objective method for assessing adverse events associated with their use, and in future studies can be actively used to monitor the safety of various therapy regimens. Wider introduction of this index in the management of patients with SLE will allow to optimize approaches to the selection of GC doses, to consider earlier prescription of biologic disease modifying antirheumatic drugs, before the development of severe irreversible damage.Keywords
This publication has 26 references indexed in Scilit:
- Brief Report: Lupus—An Unrecognized Leading Cause of Death in Young Females: A Population‐Based Study Using Nationwide Death Certificates, 2000–2015Arthritis & Rheumatology, 2018
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic AsthmaThe New England Journal of Medicine, 2014
- Glucocorticoid Receptor Function Regulated by Coordinated Action of the Hsp90 and Hsp70 Chaperone CyclesCell, 2014
- Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature ReviewClinical Therapeutics, 2011
- Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidityMusculoskeletal Care, 2007
- Very low‐dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2005
- Glucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of actionArthritis & Rheumatism, 2004
- Intravenous pulses of methylprednisolone for systemic lupus erythematosusSeminars in Arthritis and Rheumatism, 2003
- Damage in systemic lupus erythematosus and its association with corticosteroidsArthritis & Rheumatism, 2000
- Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system diseaseArthritis & Rheumatism, 1996